

Neoadjuvant Chemotherapy for Colorectal Liver Metastases: A Coi





ALL

IMAGES

VIDEOS

40,400 Results

Neoadjuvant chemotherapy in the management of colorectal ...

https://www.ncbi.nlm.nih.gov/pubmed/12772524

Neoadjuvant chemotherapy in the management of colorectal metastases: A review of the literature. ... Five-year survival rates of between 20% and 45% are achievable in patients following hepatectomy for liver metastases from colorectal cancer. Sadly, a great majority of patients present with unresectable liver disease with virtually no long-term ...

Cited by: 11 Author: S Y K Ong

Publish Year: 2003

The Role of Neoadjuvant Chemotherapy in Repeat Local ...

https://pubmed.ncbi.nlm.nih.gov/33561088

The additive value of neoadjuvant chemotherapy (NAC) prior to repeat local treatment of patients with recurrent colorectal liver metastases (CRLM) is unclear. A systematic search was performed in PubMed, Embase, Web of Science, and an additional search in Google Scholar to find articles comparing re...

Author: Madelon Dijkstra, Sanne Nieuwenhuizen, R...

Publish Year: 2021

Images of Neoadjuvant chemotherapy for colorectal liver Metasta... bing.com/images














Neoadjuvant chemotherapy for resectable colorectal liver ... https://pubmed.ncbi.nlm.nih.gov/25257725

January 2003 up to and including January 2014 regarding patients with initially ...

Background: The role of preoperative **chemotherapy** for resectable **colorectal liver metastases** is still highly controversial. The purpose of this systematic **review** is to summarize the current evidence on this topic. Methods: A systematic **literature** search was performed to identify all studies published from

Neoadjuvant chemotherapy in the management of colorectal ...

https://www.ncbi.nlm.nih.gov/pubmed/12772524

Neoadjuvant chemotherapy in the management of colorectal metastases: A review of the literature. ... Five-year survival rates of between 20% and 45% are achievable in patients following hepatectomy for liver metastases from colorectal cancer. Sadly, a great majority of patients present with unresectable liver disease with virtually no long-term ...

Cited by: 11 Author: S Y K Ong

Publish Year: 2003



Feedback

Systematic review of randomized and nonrandomized trials ... https://pubmed.ncbi.nlm.nih.gov/19856028

Background: Neoadjuvant chemotherapy prior to hepatectomy in patients with resectable colorectal liver metastases (CLM) may facilitate the resectability of the liver lesions and treat occult metastasis but may also lead to hepatic parenchyma damage. There is argument over the oncologic benefit of this practice in patients who would already be suitable for a curative hepatectomy.

Cited by 111

Author Torongo C Chua Alcahat Cayana Minat